Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from AbbVie, Inc.

Medical Crossfire®: The Advancing Role of Immunomodulatory Therapies in Modern Medicine

Release Date: September 18, 2020
Expiration Date: September 18, 2021

Activity Overview

Medical Crossfire™, one of the signature education formats of Physicians’ Education Resource®, LLC (PER®), is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders from the specialties of dermatology, rheumatology, and gastroenterology explore the latest data regarding current and emerging therapeutic strategies for the management of several immune-mediated inflammatory diseases, including atopic dermatitis, psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with these clinical conditions.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AbbVie, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward primary care physicians, rheumatologists, gastroenterologists, and dermatologists.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the overlapping characteristics for the immune-mediated inflammatory diseases (IMIDs) atopic dermatitis, psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD)
  • Identify common inflammatory pathways that are therapeutic targets for treating IMIDs
  • Identify current trends in the research and development of immunomodulatory therapies for IMIDs
  • Apply efficacy and safety findings to the clinical management of patients with atopic dermatitis, psoriasis, psoriatic arthritis, or IBD

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Mark G. Lebwohl, MD
Mark G. Lebwohl, MD
Waldman Professor and Chairman
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant/Research: AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, Leo Pharmaceuticals, Orth Dermatologics, Pfizer, UCB; Consultant: Aditum Bio, Allergan, Almirall, Arcutis Biotherapeutics, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo Therapeutics, Mitsubishi Tanabe Pharma, NeuroDerm, Pfizer, Promius Pharma/Dr. Reddy’s Laboratories, Theravance Biopharma, Verrica Pharmaceuticals.

Margaret A. Bobonich, DNP, FNP-C, DCNP, FAANP
Margaret A. Bobonich, DNP, FNP-C, DCNP, FAANP
Assistant Professor, Department of Dermatology
Case Western Reserve University School of Medicine
Frances Payne Bolton School of Nursing
University Hospitals Cleveland Medical Center
Cleveland, OH

Disclosures: Consultant: AbbVie, AstraZeneca, Janssen Pharmaceuticals, Sol-Gel Technologies; Speaker’s Bureau: AbbVie, Eli Lilly, UCB.

M. Elaine Husni, MD, MPH
M. Elaine Husni, MD, MPH
Vice Chair, Department of Rheumatology
Director, Arthritis and Musculoskeletal Center
Staff Physician, Orthopedic and Rheumatologic Institute
Cleveland Clinic
Assistant Professor
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Disclosures: Consultant: AbbVie, Bristol Myers Squibb, Novartis, Eli Lilly, Janssen Pharmaceuticals, Pfizer, UCB.

Bruce E. Sands, MD, MS
Bruce E. Sands, MD, MS
Dr Burrill B. Crohn Professor of Medicine
Director, Digestive Disease Institute
Chief, Dr Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY

Disclosures: Consulting: AbbVie, Arena Pharmaceuticals, AstraZeneca LP, Boehringer Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare Co Ltd, F. Hoffmann-La Roche, Genentech, Inc, Immunic AG, Ironwood Pharmaceuticals, Inc, Janssen Biotech, Eli Lilly, Morphic Therapeutic, Oppilan Pharma, Ltd, OSE Immunotherapeutics, Otsuka, Pfizer, Prometheus Laboratories, RedHill Biopharma, Ltd, Shire, Takeda, TARGET PharmaSolutions, Theravance Biopharma, Inc.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By